In 2014, 39% of adults worldwide were overweight and 13% were obese (Body Mass Index above 30). In the EU, US and Japan around 1/3 of the total population are suffering from elevated blood glucose levels. In the US, the prevalence of overweight is more than 60% and the type 2 diabetes prevalence is around 10%. Overweight and obesity are closely related to diabetes as evidenced by 80-85% of diabetics being overweight. Source: WHO/CDC.
Increased awareness of obesity and the associated risk of elevated blood sugar levels will drive the demand and market for health care nutrition products, which focus on the management of diabetes. Glycemicon intends to meet this demand with its nutraceutical product. This represents a commercial opportunity that Glycemicon will pursue with its nutraceutical product.